<DOC>
	<DOCNO>NCT01195038</DOCNO>
	<brief_summary>The study design assess immunogenicity safety one booster vaccination 45 Î¼g recombinant H5N1 influenza ( A/Indonesia/05/2005 ) HA vaccine healthy young adult , previously prim two-vaccination 3 different dos recombinant H5N1 influenza ( A/Vietnam/1203/2004 ) HA vaccine prim study ( JPIP501-01a , NCT00980447 ) .</brief_summary>
	<brief_title>Immunogenicity Safety Study Booster Vaccination With Recombinant H5N1 Influenza HA Vaccine Primed Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects complete prim study ( JPIP50101a , NCT00980447 ) Male female healthy adult Written inform consent obtain subject study entry History H5N1 influenza vaccination H5N1 influenza vaccine Clinically diagnose cardiovascular , hematological , psychological , neurological , hepatic , renal , pulmonary ( include asthma ) , endocrinological gastrointestinal disorder Confirmed immune deficiency condition , diagnose autoimmune disease rheumatoid arthritis systemic lupus erythematosus Severe allergic reaction anaphylaxis food drug ( include vaccine ) Treatment disallow drug include study drug Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Avian influenza , H5N1 , pandemic , recombinant HA vaccine</keyword>
</DOC>